Brookline initiated coverage of Palisade Bio (PALI) with a Buy rating and $38 price target Palisade Bio is advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, the analyst noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI:
- Palisade Bio price target lowered to $8 from $22.50 at Maxim
- Palisade Bio reports Q3 EPS ($2.32) vs. ($7.38) last year
- Palisade Bio expects cash to fund operations through 1Q25
- Palisade Bio announces first subject dosed in Phase 1 study of PALI-2108
- Palisade Bio announces data from two ex vivo studies of PALI-2108